Amneal Pharmaceuticals (AMRX) Cash from Operations (2017 - 2026)

Amneal Pharmaceuticals' Cash from Operations history runs 10 years deep, the most recent figure standing at 26743000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 461.0% year-over-year to 26743000.0; the TTM figure through Mar 2026 stood at 305841000.0 (changed 0.35% YoY), while the FY2025 annual figure was 339992000.0, up 15.21% from the prior year.
• Cash from Operations was 26743000.0 for Q1 2026 at Amneal Pharmaceuticals, down from 130315000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 141774000.0 in Q3 2024 to a low of 125521000.0 in Q2 2022.
• Historically, Cash from Operations has averaged 59942647.06 across 5 years, with a median of 83819000.0 in 2025.
• The sharpest annual moves came in 2023 and 2026: Cash from Operations jumped 683.13% in 2023, then sank 461.0% in 2026.
• A 5-year view of Cash from Operations shows it stood at 23292000.0 in 2022, then surged by 683.13% to 135823000.0 in 2023, then dropped by 13.06% to 118078000.0 in 2024, then increased by 10.36% to 130315000.0 in 2025, then slumped by 120.52% to 26743000.0 in 2026.
• The last three Cash from Operations figures came in at 26743000.0 (Q1 2026), 130315000.0 (Q4 2025), and 118450000.0 (Q3 2025), per Business Quant data.